Bite: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(9 intermediate revisions by 4 users not shown)
Line 20: Line 20:
Almost every bite will have a polimicrobial contamination and some bites have characteristic pathogens associated to the oral flora of the animal that bit.
Almost every bite will have a polimicrobial contamination and some bites have characteristic pathogens associated to the oral flora of the animal that bit.


{| class="wikitable"
{| style="border: 0px; font-size: 85%; margin: 3px;" align="center"
|+''Most common pathogens according to the type of bite''
|+''Most common pathogens according to the type of bite''
! style="width: 120px;background: #4479BA"|{{fontcolor|#FFF| Bite}} !!style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| Most Common Pathogens}}
! style="width: 100px;background: #4479BA" |{{fontcolor|#FFF| Bite}} !! style="width: 500px;background: #4479BA" |{{fontcolor|#FFF| Most Common Pathogens}}
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Human|| ''[[Viridans streptococci]], [[S. epidermidis]], [[Corynebacterium]], [[S. aureus]], [[Eikenella]], [[Bacteroides]], Peptostreptococci ''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Human
| style="width: 120px;background: #F5F5F5" |''[[Viridans streptococci]], [[S. epidermidis]], [[Corynebacterium]], [[S. aureus]], [[Eikenella]], [[Bacteroides]], Peptostreptococci ''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Dog || ''[[Pasteurella|Pasteurella canis]],[[Pasteurella multocida]], [[S. aureus]] , [[Streptococci]] , [[Anaerobes]] ([[Bacteroides|Bacteroides spp]], [[Fusobacterium]], Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci) ''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Dog
| style="width: 120px;background: #F5F5F5" | ''[[Pasteurella|Pasteurella canis]],[[Pasteurella multocida]], [[S. aureus]] , [[Streptococci]] , [[Anaerobes]] ([[Bacteroides|Bacteroides spp]], [[Fusobacterium]], Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci) ''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Cat ||''[[Pasteurella multocida]], [[S. aureus]], [[Streptococci]] , [[Anaerobes]] ([[Bacteroides|Bacteroides spp]], [[Fusobacterium]], Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci)''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Cat
| style="width: 120px;background: #F5F5F5" |''[[Pasteurella multocida]], [[S. aureus]], [[Streptococci]] , [[Anaerobes]] ([[Bacteroides|Bacteroides spp]], [[Fusobacterium]], Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci)''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Pig || ''[[Pasteurella|Pasteurella spp]], [[Gram-negative bacilli]], [[Gram-positive bacteria|Gram-positive cocci]], [[Anaerobes]]''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Pig
| style="width: 120px;background: #F5F5F5" |''[[Pasteurella|Pasteurella spp]], [[Gram-negative bacilli]], [[Gram-positive bacteria|Gram-positive cocci]], [[Anaerobes]]''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Monkey || ''[[Herpesvirus simiae]] ([[Monkey B virus|B Virus]])''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Monkey
| style="width: 120px;background: #F5F5F5" | ''[[Herpesvirus simiae]] ([[Monkey B virus|B Virus]])''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Rat ||''[[Spirillum|Spirillum minus]], [[Streptobacillus|Streptobacillus moniliformis]]''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Rat
| style="width: 120px;background: #F5F5F5" |''[[Spirillum|Spirillum minus]], [[Streptobacillus|Streptobacillus moniliformis]]''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Seal||''[[Mycoplasma|Mycoplasma spp]]''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Seal
| style="width: 120px;background: #F5F5F5" |''[[Mycoplasma|Mycoplasma spp]]''
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Camel || ''[[S. aureus]], [[S. epidermidis]], [[Moraxella catarrhalis]], [[Klebsiella pneumoniae]], [[S. pyogenes]],[[E. coli]], [[Pseudomonas aeruginosa]], [[Bacillus spp]].''
| style="width: 100px;font-weight: bold;background: #DCDCDC" |Camel
| style="width: 120px;background: #F5F5F5" |''[[S. aureus]], [[S. epidermidis]], [[Moraxella catarrhalis]], [[Klebsiella pneumoniae]], [[S. pyogenes]],[[E. coli]], [[Pseudomonas aeruginosa]], [[Bacillus spp]].''
|}
|}


Line 49: Line 57:
*The [[route of administration]] depends on the depth and severity of the [[wound]], as well as the time that has passed since the bite.
*The [[route of administration]] depends on the depth and severity of the [[wound]], as well as the time that has passed since the bite.


===Antibiotic Therapy<small><small><small><small>Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005<ref name=IDSA2005>{{Cite journal
===Antibiotic Therapy<small><small><small><small>Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005<ref name="IDSA2005">{{Cite journal
  | author = Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade
  | author = Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade
  | title = Practice guidelines for the diagnosis and management of skin and soft-tissue infections
  | title = Practice guidelines for the diagnosis and management of skin and soft-tissue infections
Line 61: Line 69:
  | pmid = 16231249
  | pmid = 16231249
}}</ref></small></small></small></small>===
}}</ref></small></small></small></small>===
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></small>
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
| valign=top |
| valign="top" |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #4479BA; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #4479BA; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
Line 149: Line 157:
</div>
</div>


| valign=top |
| valign="top" |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table00" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Antibiotic Prophylaxis}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Antibiotic Prophylaxis}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Preferred Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300 mg q8h'''''<br> OR <br> ▸ '''''[[Metronidazole]] 500 mg PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Clindamycin]] 300 mg q8h'''''<br> OR <br> ▸ '''''[[Metronidazole]] 500 mg PO q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg q12h'''''<br> OR <br> ▸ '''''[[TMP-SMX]] 160/800 mg PO q12h'''''<br> OR <br> ▸ '''''[[Penicillin VK]] 500 mg PO q6h'''''<br> OR <br> ▸ '''''[[Cefuroxime]] 500 mg PO q12h'''''<br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg PO q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg q12h'''''<br> OR <br> ▸ '''''[[TMP-SMX]] 160/800 mg PO q12h'''''<br> OR <br> ▸ '''''[[Penicillin VK]] 500 mg PO q6h'''''<br> OR <br> ▸ '''''[[Cefuroxime]] 500 mg PO q12h'''''<br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg PO q24h'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Human Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Human Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 2 gm IV q8h'''''<BR> OR <BR> ▸ '''''[[Ticarcillin clavulanate]] 3.1 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Piperacillin-tazobactam]] 3.375 g IV q6-8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ampicillin sulbactam]] 1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 2 gm IV q8h'''''<BR> OR <BR> ▸ '''''[[Ticarcillin clavulanate]] 3.1 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Piperacillin-tazobactam]] 3.375 g IV q6-8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen (beta-lactam allergy)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300 mg PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Clindamycin]] 300 mg PO q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 500-750 mg IV q12h''''' <br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' <br> OR <br> ▸ '''''[[TMP-SMX]] 160/800 mg q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ciprofloxacin]] 500-750 mg IV q12h''''' <br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' <br> OR <br> ▸ '''''[[TMP-SMX]] 160/800 mg q12h'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Dog Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Dog Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen (beta-lactam allergy)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸  '''''[[Clindamycin]] 300 mg PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸  '''''[[Clindamycin]] 300 mg PO q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 500-750 mg IV q12h''''' <br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' <br> OR <br> ▸ '''''[[Gatifloxacin]] 400 mg q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ciprofloxacin]] 500-750 mg IV q12h''''' <br> OR <br> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h''''' <br> OR <br> ▸ '''''[[Gatifloxacin]] 400 mg q24h'''''
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cat Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Cat Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 500-875/125 PO q8-12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen (beta-lactam allergy)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] 500 mg q12h''''' <br> OR <br>▸ '''''[[Doxycycline]] 100 mg q12h'''''  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Cefuroxime]] 500 mg q12h''''' <br> OR <br>▸ '''''[[Doxycycline]] 100 mg q12h'''''  
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table04" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Pig (Swine) Bite }}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Pig (Swine) Bite }}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 1.5 to 3 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 1 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 1 g q12 h''''' <BR> OR <BR> ▸ '''''[[Cefotaxime]] 2 g q6 h''''' <BR> OR <BR> ▸ '''''[[Ticarcillin clavulanate]] 3.1 g IV q6hr'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ampicillin sulbactam]] 1.5 to 3 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 1 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 1 g q12 h''''' <BR> OR <BR> ▸ '''''[[Cefotaxime]] 2 g q6 h''''' <BR> OR <BR> ▸ '''''[[Ticarcillin clavulanate]] 3.1 g IV q6hr'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table05" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Monkey / Primate Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Monkey / Primate Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Profilaxis
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Profilaxis
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Valacyclovir]]  1 g PO q8h x 14 days'''''<BR> OR <BR> ▸ '''''[[Acyclovir]] 800 mg PO 5 times/day'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Valacyclovir]]  1 g PO q8h x 14 days'''''<BR> OR <BR> ▸ '''''[[Acyclovir]] 800 mg PO 5 times/day'''''
|-
|-
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen (without CNS symptoms)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen (without CNS symptoms)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]]  12.5–15 mg per kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Acyclovir]]  12.5–15 mg per kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen (with CNS symptoms)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen (with CNS symptoms)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left | ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" | ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | <small> Adapted from Prevention of and Therapy for B Virus Exposure • CID 2002:35<ref name="CohenDavenport2002">{{cite journal|last1=Cohen|first1=Jeffrey I.|last2=Davenport|first2=David S.|last3=Stewart|first3=John A.|last4=Deitchman|first4=Scott|last5=Hilliard|first5=Julia K.|last6=Chapman|first6=Louisa E.|title=Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine Herpesvirus1)|journal=Clinical Infectious Diseases|volume=35|issue=10|year=2002|pages=1191–1203|issn=1058-4838|doi=10.1086/344754}}</ref></small>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | <small> Adapted from Prevention of and Therapy for B Virus Exposure • CID 2002:35<ref name="CohenDavenport2002">{{cite journal|last1=Cohen|first1=Jeffrey I.|last2=Davenport|first2=David S.|last3=Stewart|first3=John A.|last4=Deitchman|first4=Scott|last5=Hilliard|first5=Julia K.|last6=Chapman|first6=Louisa E.|title=Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine Herpesvirus1)|journal=Clinical Infectious Diseases|volume=35|issue=10|year=2002|pages=1191–1203|issn=1058-4838|doi=10.1086/344754}}</ref></small>
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table06" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Uncomplicated Rat Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Uncomplicated Rat Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen (beta-lactam allergy)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
|-
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Rat Bite Fever}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Rat Bite Fever}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin G]] 400,000 - 600,000 IU/day IV x 10-14 days (dose should be increased to 1.2 M if no clinical response)'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Penicillin G]] 400,000 - 600,000 IU/day IV x 10-14 days (dose should be increased to 1.2 M if no clinical response)'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Streptomycin]] 15 mg/kg/day IM divided q12-24h x 10-14 days'''''<BR> OR <BR> ▸ '''''[[Tetracycline]]  250 to 500 mg orally q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Streptomycin]] 15 mg/kg/day IM divided q12-24h x 10-14 days'''''<BR> OR <BR> ▸ '''''[[Tetracycline]]  250 to 500 mg orally q6h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small> Adapted from Clin. Microbiol. Rev. January 2007 vol.20 no.1 13-22 <ref name="Elliott2007">{{cite journal|last1=Elliott|first1=S. P.|title=Rat Bite Fever and Streptobacillus moniliformis|journal=Clinical Microbiology Reviews|volume=20|issue=1|year=2007|pages=13–22|issn=0893-8512|doi=10.1128/CMR.00016-06}}</ref></small>
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" |<small> Adapted from Clin. Microbiol. Rev. January 2007 vol.20 no.1 13-22 <ref name="Elliott2007">{{cite journal|last1=Elliott|first1=S. P.|title=Rat Bite Fever and Streptobacillus moniliformis|journal=Clinical Microbiology Reviews|volume=20|issue=1|year=2007|pages=13–22|issn=0893-8512|doi=10.1128/CMR.00016-06}}</ref></small>
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table08" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Seal Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Seal Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Preferred Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Tetracycline]] 1.5 g 1 dose, then 0.5 g q6h x 4-6 weeks'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Tetracycline]] 1.5 g 1 dose, then 0.5 g q6h x 4-6 weeks'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Alternative Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg q12h x 4-6 weeks'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg q12h x 4-6 weeks'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;align=left |<small> Adapted from Journal of Infection (2002) 45: 71±75 <ref name="HartleyPitcher2002">{{cite journal|last1=Hartley|first1=J.W.|last2=Pitcher|first2=D.|title=Seal Finger—Tetracycline is First Line|journal=Journal of Infection|volume=45|issue=2|year=2002|pages=71–75|issn=01634453|doi=10.1053/jinf.2002.1027}}</ref></small>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;align=left " |<small> Adapted from Journal of Infection (2002) 45: 71±75 <ref name="HartleyPitcher2002">{{cite journal|last1=Hartley|first1=J.W.|last2=Pitcher|first2=D.|title=Seal Finger—Tetracycline is First Line|journal=Journal of Infection|volume=45|issue=2|year=2002|pages=71–75|issn=01634453|doi=10.1053/jinf.2002.1027}}</ref></small>
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table09" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Camel Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Camel Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Preferred Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Dicloxacillin]] 250–500 mg PO q6h      '''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Dicloxacillin]] 250–500 mg PO q6h      '''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 750 mg PO q12h      '''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ciprofloxacin]] 750 mg PO q12h      '''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen '''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Alternative Regimen  
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cephalexin]] 500 mg PO q6h      '''''  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Cephalexin]] 500 mg PO q6h      '''''  
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 750 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Ciprofloxacin]] 750 mg PO q12h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left | <small>Adapted from ''Eur J Clin Microbiol Infect Dis. 1999;18(12):918-9.''<ref name="BadejoO. Komolafe &#134;, &#135; , D. L.1999">{{cite journal|last1=Badejo|first1=O. A.|last2=O. Komolafe &#134;, &#135; , D. L.|first2=O.|title=Bacteriology and Clinical Course of Camel-Bite Wound Infections|journal=European Journal of Clinical Microbiology & Infectious Diseases|volume=18|issue=12|year=1999|pages=918–919|issn=0934-9723|doi=10.1007/s100960050433}}</ref></small>
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align="left" | <small>Adapted from ''Eur J Clin Microbiol Infect Dis. 1999;18(12):918-9.''<ref name="BadejoO. Komolafe &amp;#134;, &amp;#135; , D. L.1999">{{cite journal|last1=Badejo|first1=O. A.|last2=O. Komolafe &#134;, &#135; , D. L.|first2=O.|title=Bacteriology and Clinical Course of Camel-Bite Wound Infections|journal=European Journal of Clinical Microbiology & Infectious Diseases|volume=18|issue=12|year=1999|pages=918–919|issn=0934-9723|doi=10.1007/s100960050433}}</ref></small>
       |-
       |-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table10" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Bat Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Bat Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table11" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Racoon Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Racoon Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
|-
|-
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table12" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Skunk Bite}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Skunk Bite}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | '''''Alternative Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
|-
|-
|}
|}
Line 374: Line 382:


==Vaccination==
==Vaccination==
===Tetanus Prophylaxis===
===Tetanus Prophylaxis <small><small><small><small>Adapted from CDC Vaccines and Immunizations - Tetanus <ref name="tetanus">{{cite web| title=CDC Vaccines and Immunizations - Tetanus | url=http://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html#schedule}} </ref></small></small></small></small>===


The need for [[active immunization]], with or without [[passive immunization]], depends on the condition of the wound and the patient’s [[immunization]] history.
The need for [[active immunization]], with or without [[passive immunization]], depends on the condition of the wound and the patient’s [[immunization]] history.
The following table summarizes the indications for [[tetanus]] prophylaxis.
The following table summarizes the indications for [[tetanus]] prophylaxis.


{| style="border: 0px; font-size: 85%; margin: 3px;" align=center
{| style="border: 0px; font-size: 85%; margin: 3px;" align="center"
! style="width: 200px;background: #4479BA" rowspan=2|{{fontcolor|#FFF|Vaccination History }}
! rowspan="2" style="width: 200px;background: #4479BA" |{{fontcolor|#FFF|Vaccination History }}
! style="width: 200px;background: #4479BA" colspan=2|{{fontcolor|#FFF|Clean, minor wounds}}
! colspan="2" style="width: 200px;background: #4479BA" |{{fontcolor|#FFF|Clean, minor wounds}}
! style="width: 200px;background: #4479BA" colspan=2|{{fontcolor|#FFF|All other wounds}}
! colspan="2" style="width: 200px;background: #4479BA" |{{fontcolor|#FFF|All other wounds}}
|-
|-
| style="width: 120px;background: #4479BA; text-align:center"|{{fontcolor|#FFF|'''Td'''}}
| style="width: 120px;background: #4479BA; text-align:center" |{{fontcolor|#FFF|'''Td<sup>†</sup>'''}}
| style="width: 120px;background: #4479BA; text-align:center"|{{fontcolor|#FFF|'''TIG'''}}
| style="width: 120px;background: #4479BA; text-align:center" |{{fontcolor|#FFF|'''Tetanus immune globulin (TIG)'''}}
| style="width: 120px;background: #4479BA; text-align:center"|{{fontcolor|#FFF|'''Td'''}}
| style="width: 120px;background: #4479BA; text-align:center" |{{fontcolor|#FFF|'''Td<sup>†</sup>'''}}
| style="width: 120px;background: #4479BA; text-align:center"|{{fontcolor|#FFF|'''TIG'''}}
| style="width: 120px;background: #4479BA; text-align:center" |{{fontcolor|#FFF|'''Tetanus immune globulin (TIG)'''}}
|-
|-
| style="width: 120px;background: #F5F5F5"|'''Unknown or less than 3 doses'''
| style="width: 120px;background: #F5F5F5" |'''Unknown or less than 3 doses'''
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
|-
|-
| style="width: 120px;background: #F5F5F5"|'''3 or more doses'''
| style="width: 120px;background: #F5F5F5" |'''3 or more doses'''
| style="width: 120px;background: #F5F5F5"|
| style="width: 120px;background: #F5F5F5" |
| style="width: 120px;background: #F5F5F5"|
| style="width: 120px;background: #F5F5F5" |
| style="width: 120px;background: #F5F5F5"|
| style="width: 120px;background: #F5F5F5" |
| style="width: 120px;background: #F5F5F5"|
| style="width: 120px;background: #F5F5F5" |
|-
|-
| style="width: 120px;background: #F5F5F5"|&nbsp;&nbsp;&nbsp;&nbsp; If > 10 yrs since last dose
| style="width: 120px;background: #F5F5F5" |&nbsp;&nbsp;&nbsp;&nbsp; If > 10 yrs since last dose
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
|-
|-
| style="width: 120px;background: #F5F5F5"|&nbsp;&nbsp;&nbsp;&nbsp; If > 5 yrs since last dose
| style="width: 120px;background: #F5F5F5" |&nbsp;&nbsp;&nbsp;&nbsp; If > 5 yrs since last dose
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
| style="width: 120px;background: #F5F5F5; text-align:center"|YES
| style="width: 120px;background: #F5F5F5; text-align:center" |YES
| style="width: 120px;background: #F5F5F5; text-align:center"|NO
| style="width: 120px;background: #F5F5F5; text-align:center" |NO
|-
|-
 
| colspan="5" style="width: 120px;background: #F5F5F5" |<small><sup>†</sup>Tdap may be substituted for Td if the person has not previously received Tdap and is 10 years or older</small>
 
|-
 
| colspan="5" style="width: 120px;background: #F5F5F5" |<small> Table adapted from CDC Vaccines and Immunizations - Tetanus <ref name="tetanus">{{cite web| title=CDC Vaccines and Immunizations - Tetanus | url=http://www.cdc.gov/vaccines/pubs/pinkbook/tetanus.html#schedule}} </ref></small>
|}
|}


Line 433: Line 441:
* Red eyes.
* Red eyes.


{| class="wikitable"
{| style="border: 0px; font-size: 85%; margin: 3px;" align="center"
|+ ''Indications for rabies prophylaxis''<ref name="ACIP">{{Cite web| title = Advisory Committee on Immunization Practices (ACIP) for postexposure prophylaxis (PEP) to prevent human rabies (CDC. Human rabies prevention) | url = http://www.cdc.gov/rabies/resources/acip_recommendations.html}}</ref>
|+ ''Indications for rabies prophylaxis''<ref name="ACIP">{{Cite web| title = Advisory Committee on Immunization Practices (ACIP) for postexposure prophylaxis (PEP) to prevent human rabies (CDC. Human rabies prevention) | url = http://www.cdc.gov/rabies/resources/acip_recommendations.html}}</ref>
! style="width: 250px;background: #4479BA"|{{fontcolor|#FFF| Animal Type}}
! style="width: 250px;background: #4479BA" |{{fontcolor|#FFF| Animal Type}}
! style="width: 200px;background: #4479BA"|{{fontcolor|#FFF| Evaluation of the Animal}}
! style="width: 200px;background: #4479BA" |{{fontcolor|#FFF| Evaluation of the Animal}}
! style="width: 400px;background: #4479BA"|{{fontcolor|#FFF| Prophylaxis Recommendation}}
! style="width: 400px;background: #4479BA" |{{fontcolor|#FFF| Prophylaxis Recommendation}}
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC" rowspan=3|Dog, cat, ferret
| rowspan="3" style="width: 120px;font-weight: bold;background: #DCDCDC" |Dog, cat, ferret
| Healthy and available for observation for 10 days
| style="width: 120px;background: #F5F5F5" |Healthy and available for observation for 10 days
| Prophylaxis should not be started unless the animal develops symptoms <br> If rabies symptoms develop, immediately begin rabies prophylaxis
| style="width: 120px;background: #F5F5F5" |Prophylaxis should not be started unless the animal develops symptoms <br> If rabies symptoms develop, immediately begin rabies prophylaxis
|-
|-
|Confirmed or suspected rabies infection
| style="width: 120px;background: #F5F5F5" |Confirmed or suspected rabies infection
|Immediately begin rabies prophylaxis
| style="width: 120px;background: #F5F5F5" |Immediately begin rabies prophylaxis
|-
|-
| Unknown
| style="width: 120px;background: #F5F5F5" |Unknown
| Immediately begin rabies prophylaxis
| style="width: 120px;background: #F5F5F5" |Immediately begin rabies prophylaxis
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"| Skunk, raccoon, bat, fox, coyote, other carnivores
| style="width: 120px;font-weight: bold;background: #DCDCDC" | Skunk, raccoon, bat, fox, coyote, other carnivores
| Considered as rabies infection
| style="width: 120px;background: #F5F5F5" |Considered as rabies infection
| Immediately begin rabies prophylaxis
| style="width: 120px;background: #F5F5F5" |Immediately begin rabies prophylaxis
|-
|-
| style="width: 120px;font-weight: bold;background: #DCDCDC"|Livestock, rodents, rabbit, squirrels, hamster, guinea pig, gerbil, chipmunk, rat, mouse, woodchuck
| style="width: 120px;font-weight: bold;background: #DCDCDC" |Livestock, rodents, rabbit, squirrels, hamster, guinea pig, gerbil, chipmunk, rat, mouse, woodchuck
|
| style="width: 120px;background: #F5F5F5" |
| Almost never require anti-rabies prophylaxis, but consult public health officials
| style="width: 120px;background: #F5F5F5" |Almost never require anti-rabies prophylaxis, but consult public health officials
|}
|}


 
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand prophylactic regimens.'''</font></SMALL>
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand prophylactic regimens.'''</font></small>


{|
{|
| valign=top |
| valign="top" |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #4479BA; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 260px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #4479BA; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 260px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
Line 481: Line 488:
</div>
</div>


 
| valign="top" |
| valign=top |
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table15" style="background: #FFFFFF;"
| valign="top" |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Patient Not Previously Vaccinated}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Patient Not Previously Vaccinated}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Prophylactic Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Prophylactic Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Wound cleansing'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''Wound cleansing'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Human rabies immune globulin]]† (HRIG) 20 IU/kg ''''' <br> <small>If anatomically feasible, the full dose should be infiltrated around and into the wound, and any remaining volume should be administered IM </small>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''[[Human rabies immune globulin]]† (HRIG) 20 IU/kg ''''' <br> <small>If anatomically feasible, the full dose should be infiltrated around and into the wound, and any remaining volume should be administered IM </small>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Human diploid cell vaccine (HDCV) 1.0 mL IM'''''<br> OR <br> ▸ ''''' Purified chick embryo cell vaccine (PCECV) 1.0 mL IM'''''  <br>  <small> Administer 4 doses in total; on days 0, 3, 7 and 14¶ </small>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''Human diploid cell vaccine (HDCV) 1.0 mL IM'''''<br> OR <br> ▸ ''''' Purified chick embryo cell vaccine (PCECV) 1.0 mL IM'''''  <br>  <small> Administer 4 doses in total; on days 0, 3, 7 and 14¶ </small>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5"| <small>†HRIG should not be administered in the same syringe as vaccine. <br> ¶ For suppressed patients administer an additional dose on day 28</small>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" | <small>†HRIG should not be administered in the same syringe as vaccine. <br> ¶ For suppressed patients administer an additional dose on day 28</small>
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table16" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" style="background: #FFFFFF;"
| valign=top |
| valign="top" |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Patient Previously Vaccinated}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align="center" | {{fontcolor|#FFF|Patient Previously Vaccinated}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Prophylactic Regimen
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align="center" | Prophylactic Regimen
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Wound cleansing'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''Wound cleansing'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" |PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Human diploid cell vaccine (HDCV) 1.0 mL IM'''''<br> OR <br> ▸ ''''' Purified chick embryo cell vaccine (PCECV) 1.0 mL IM'''''  <br>  <small> Administer 2 doses in total; on days 0 and 3</small>
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align="left" | ▸ '''''Human diploid cell vaccine (HDCV) 1.0 mL IM'''''<br> OR <br> ▸ ''''' Purified chick embryo cell vaccine (PCECV) 1.0 mL IM'''''  <br>  <small> Administer 2 doses in total; on days 0 and 3</small>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5"| <small> HRIG should not be administered.</small>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" | <small> HRIG should not be administered.</small>
|}
|}
|}
|}
|}
|}


==Post Exposure Measures==
=== Minor wounds ===
*Wash the wound thoroughly with soap and water.
*Apply an antibiotic cream.
*Cover the wound with a clean bandage.
*See a healthcare provider if the wound becomes red, painful, warm, or swollen; if you develop a fever; or if the dog that bit you was acting strangely.
=== Deep wounds ===
*Apply pressure with a clean, dry cloth to stop the bleeding.
*If you cannot stop the bleeding or you feel faint or weak, call 911 or your local emergency medical services immediately.
*See a healthcare provider as soon as possible.<ref name="cdc">Dog Bite Prevention. CDC. http://www.cdc.gov/features/dog-bite-prevention/ Accessed on February 10, 2016  </ref>
==See Also==
==See Also==


Line 531: Line 549:


{{reflist|2}}
{{reflist|2}}
==External links==
*[http://www.emedicine.com/med/topic1033.htm Treating human bites]


{{Injuries, other than fractures, dislocations, sprains and strains}}
{{Injuries, other than fractures, dislocations, sprains and strains}}


[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]
[[Category:Injuries]]
[[Category:Injuries]]
[[Category:Primary care]]
[[Category:Veterinary medicine]]
[[Category:Veterinary medicine]]
[[Category:Wikinfect]]
[[Category:Wikinfect]]

Latest revision as of 20:37, 29 July 2020

WikiDoc Resources for Bite

Articles

Most recent articles on Bite

Most cited articles on Bite

Review articles on Bite

Articles on Bite in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bite

Images of Bite

Photos of Bite

Podcasts & MP3s on Bite

Videos on Bite

Evidence Based Medicine

Cochrane Collaboration on Bite

Bandolier on Bite

TRIP on Bite

Clinical Trials

Ongoing Trials on Bite at Clinical Trials.gov

Trial results on Bite

Clinical Trials on Bite at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bite

NICE Guidance on Bite

NHS PRODIGY Guidance

FDA on Bite

CDC on Bite

Books

Books on Bite

News

Bite in the news

Be alerted to news on Bite

News trends on Bite

Commentary

Blogs on Bite

Definitions

Definitions of Bite

Patient Resources / Community

Patient resources on Bite

Discussion groups on Bite

Patient Handouts on Bite

Directions to Hospitals Treating Bite

Risk calculators and risk factors for Bite

Healthcare Provider Resources

Symptoms of Bite

Causes & Risk Factors for Bite

Diagnostic studies for Bite

Treatment of Bite

Continuing Medical Education (CME)

CME Programs on Bite

International

Bite en Espanol

Bite en Francais

Business

Bite in the Marketplace

Patents on Bite

Experimental / Informatics

List of terms related to Bite

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

A bite is a wound received from the mouth (and in particular, the teeth) of an animal or person. Most animal bites are from dogs or cats, and the pathogens in the wound are composed by the normal oral flora of the biting animal and human skin flora.

Animals may bite in self-defense, in an attempt to predate food, as well as part of normal interactions. Other bite attacks may be apparently unprovoked, especially in the case of bites committed by psychologically or emotionally disturbed humans. Some disorders such as Lesch-Nyhan syndrome may cause people to bite themselves.

Bite wounds can be very complex and it is important to address the following aspects:

Common Pathogens

Almost every bite will have a polimicrobial contamination and some bites have characteristic pathogens associated to the oral flora of the animal that bit.

Most common pathogens according to the type of bite
Bite Most Common Pathogens
Human Viridans streptococci, S. epidermidis, Corynebacterium, S. aureus, Eikenella, Bacteroides, Peptostreptococci
Dog Pasteurella canis,Pasteurella multocida, S. aureus , Streptococci , Anaerobes (Bacteroides spp, Fusobacterium, Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci)
Cat Pasteurella multocida, S. aureus, Streptococci , Anaerobes (Bacteroides spp, Fusobacterium, Prevotella heparinolytica, Proprionibacteria, and Peptostreptococci)
Pig Pasteurella spp, Gram-negative bacilli, Gram-positive cocci, Anaerobes
Monkey Herpesvirus simiae (B Virus)
Rat Spirillum minus, Streptobacillus moniliformis
Seal Mycoplasma spp
Camel S. aureus, S. epidermidis, Moraxella catarrhalis, Klebsiella pneumoniae, S. pyogenes,E. coli, Pseudomonas aeruginosa, Bacillus spp.

Treatment

  • All bite wounds should be cleaned profusely with iodide soap and water.
  • Bites are contaminated by a polimicrobial flora and antibiotic prophylaxis treatment is recommended to avoid subsequent infection.

Antibiotic TherapyAdapted from Guidelines for Skin and Soft-Tissue Infections CID 2005[1]

▸ Click on the following categories to expand treatment regimens.

Antibiotic Prophylaxis

  ▸  Any Type of Bite

Specific Therapy

  ▸  Bat Bite

  ▸  Camel Bite

  ▸  Cat Bite

  ▸  Dog Bite

  ▸  Human Bite

  ▸  Monkey / Primate Bite

  ▸  Pig (Swine) Bite

  ▸  Racoon Bite

  ▸  Rat Bite

  ▸  Seal Bite

  ▸  Skunk Bite

Antibiotic Prophylaxis
Preferred Regimen
Amoxicillin-clavulanate 500-875/125 PO q8-12h
Alternative Regimen
Clindamycin 300 mg q8h
OR
Metronidazole 500 mg PO q8h
PLUS
Doxycycline 100 mg q12h
OR
TMP-SMX 160/800 mg PO q12h
OR
Penicillin VK 500 mg PO q6h
OR
Cefuroxime 500 mg PO q12h
OR
Moxifloxacin 400 mg PO q24h
Human Bite
Preferred Regimen
Ampicillin sulbactam 1.5 g IV q6h
OR
Cefoxitin 2 gm IV q8h
OR
Ticarcillin clavulanate 3.1 g IV q6h
OR
Piperacillin-tazobactam 3.375 g IV q6-8h
Alternative Regimen (beta-lactam allergy)
Clindamycin 300 mg PO q8h
PLUS
Ciprofloxacin 500-750 mg IV q12h
OR
Moxifloxacin 400 mg IV q24h
OR
TMP-SMX 160/800 mg q12h
Dog Bite
Preferred Regimen
Amoxicillin-clavulanate 500-875/125 PO q8-12h
Alternative Regimen (beta-lactam allergy)
Clindamycin 300 mg PO q8h
PLUS
Ciprofloxacin 500-750 mg IV q12h
OR
Moxifloxacin 400 mg IV q24h
OR
Gatifloxacin 400 mg q24h
Cat Bite
Preferred Regimen
Amoxicillin-clavulanate 500-875/125 PO q8-12h
Alternative Regimen (beta-lactam allergy)
Cefuroxime 500 mg q12h
OR
Doxycycline 100 mg q12h
Pig (Swine) Bite
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg PO q12h
Alternative Regimen
Ampicillin sulbactam 1.5 to 3 g IV q6-8h
OR
Imipenem cilastatin 1 g IV q6-8h
OR
Ceftriaxone 1 g q12 h
OR
Cefotaxime 2 g q6 h
OR
Ticarcillin clavulanate 3.1 g IV q6hr
Monkey / Primate Bite
Profilaxis
Valacyclovir 1 g PO q8h x 14 days
OR
Acyclovir 800 mg PO 5 times/day
Preferred Regimen (without CNS symptoms)
Acyclovir 12.5–15 mg per kg IV q8h
OR
Ganciclovir 5 mg per kg IV q12h
Preferred Regimen (with CNS symptoms)
Ganciclovir 5 mg per kg IV q12h
Adapted from Prevention of and Therapy for B Virus Exposure • CID 2002:35[2]
Uncomplicated Rat Bite
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg orally q12h
Alternative Regimen (beta-lactam allergy)
Doxycycline 100 mg orally q12h
Rat Bite Fever
Preferred Regimen
Penicillin G 400,000 - 600,000 IU/day IV x 10-14 days (dose should be increased to 1.2 M if no clinical response)
Alternative Regimen
Streptomycin 15 mg/kg/day IM divided q12-24h x 10-14 days
OR
Tetracycline 250 to 500 mg orally q6h
Adapted from Clin. Microbiol. Rev. January 2007 vol.20 no.1 13-22 [3]
Seal Bite
Preferred Regimen
Tetracycline 1.5 g 1 dose, then 0.5 g q6h x 4-6 weeks
Alternative Regimen
Doxycycline 100 mg q12h x 4-6 weeks
Adapted from Journal of Infection (2002) 45: 71±75 [4]
Camel Bite
Preferred Regimen
Dicloxacillin 250–500 mg PO q6h
PLUS
Ciprofloxacin 750 mg PO q12h
Alternative Regimen
Cephalexin 500 mg PO q6h
PLUS
Ciprofloxacin 750 mg PO q12h
Adapted from Eur J Clin Microbiol Infect Dis. 1999;18(12):918-9.[5]
Bat Bite
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg orally q12h
Alternative Regimen
Doxycycline 100 mg orally q12h
Racoon Bite
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg orally q12h
Alternative Regimen
Doxycycline 100 mg orally q12h
Skunk Bite
Preferred Regimen
Amoxicillin-clavulanate 875/125 mg orally q12h
Alternative Regimen
Doxycycline 100 mg orally q12h

Vaccination

Tetanus Prophylaxis Adapted from CDC Vaccines and Immunizations - Tetanus [6]

The need for active immunization, with or without passive immunization, depends on the condition of the wound and the patient’s immunization history. The following table summarizes the indications for tetanus prophylaxis.

Vaccination History Clean, minor wounds All other wounds
Td Tetanus immune globulin (TIG) Td Tetanus immune globulin (TIG)
Unknown or less than 3 doses YES NO YES YES
3 or more doses
     If > 10 yrs since last dose YES NO YES NO
     If > 5 yrs since last dose NO NO YES NO
Tdap may be substituted for Td if the person has not previously received Tdap and is 10 years or older
Table adapted from CDC Vaccines and Immunizations - Tetanus [6]

Rabies Prophylaxis Adapted from CDC - ACIP Recommendations for postexposure prophylaxis (PEP) to prevent human rabies.[7]

Animal bites inflicted by carnivores (except rodents) are considered possible cases of rabies. The animal is caught alive or dead with its head preserved, so the head can later be analyzed to detect the disease.

If the animal lives for ten days and does not develop rabies, then it is probable that no rabies infection has occurred.

If the animal is gone, prophylactic rabies treatment is recommended.

Signs of animal rabies include:

  • Foaming at the mouth
  • Self-mutilation
  • Growling
  • Jerky behavior
  • Red eyes.
Indications for rabies prophylaxis[7]
Animal Type Evaluation of the Animal Prophylaxis Recommendation
Dog, cat, ferret Healthy and available for observation for 10 days Prophylaxis should not be started unless the animal develops symptoms
If rabies symptoms develop, immediately begin rabies prophylaxis
Confirmed or suspected rabies infection Immediately begin rabies prophylaxis
Unknown Immediately begin rabies prophylaxis
Skunk, raccoon, bat, fox, coyote, other carnivores Considered as rabies infection Immediately begin rabies prophylaxis
Livestock, rodents, rabbit, squirrels, hamster, guinea pig, gerbil, chipmunk, rat, mouse, woodchuck Almost never require anti-rabies prophylaxis, but consult public health officials

▸ Click on the following categories to expand prophylactic regimens.

Rabies Prophylaxis

  ▸  Patient Not Previously Vaccinated

  ▸  Patient Previously Vaccinated

Patient Not Previously Vaccinated
Prophylactic Regimen
Wound cleansing
PLUS
Human rabies immune globulin† (HRIG) 20 IU/kg
If anatomically feasible, the full dose should be infiltrated around and into the wound, and any remaining volume should be administered IM
PLUS
Human diploid cell vaccine (HDCV) 1.0 mL IM
OR
Purified chick embryo cell vaccine (PCECV) 1.0 mL IM
Administer 4 doses in total; on days 0, 3, 7 and 14¶
†HRIG should not be administered in the same syringe as vaccine.
¶ For suppressed patients administer an additional dose on day 28
Patient Previously Vaccinated
Prophylactic Regimen
Wound cleansing
PLUS
Human diploid cell vaccine (HDCV) 1.0 mL IM
OR
Purified chick embryo cell vaccine (PCECV) 1.0 mL IM
Administer 2 doses in total; on days 0 and 3
HRIG should not be administered.

Post Exposure Measures

Minor wounds

  • Wash the wound thoroughly with soap and water.
  • Apply an antibiotic cream.
  • Cover the wound with a clean bandage.
  • See a healthcare provider if the wound becomes red, painful, warm, or swollen; if you develop a fever; or if the dog that bit you was acting strangely.

Deep wounds

  • Apply pressure with a clean, dry cloth to stop the bleeding.
  • If you cannot stop the bleeding or you feel faint or weak, call 911 or your local emergency medical services immediately.
  • See a healthcare provider as soon as possible.[8]

See Also

References

  1. Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)
  2. Cohen, Jeffrey I.; Davenport, David S.; Stewart, John A.; Deitchman, Scott; Hilliard, Julia K.; Chapman, Louisa E. (2002). "Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine Herpesvirus1)". Clinical Infectious Diseases. 35 (10): 1191–1203. doi:10.1086/344754. ISSN 1058-4838.
  3. Elliott, S. P. (2007). "Rat Bite Fever and Streptobacillus moniliformis". Clinical Microbiology Reviews. 20 (1): 13–22. doi:10.1128/CMR.00016-06. ISSN 0893-8512.
  4. Hartley, J.W.; Pitcher, D. (2002). "Seal Finger—Tetracycline is First Line". Journal of Infection. 45 (2): 71–75. doi:10.1053/jinf.2002.1027. ISSN 0163-4453.
  5. Badejo, O. A.; O. Komolafe &#134;, &#135; , D. L., O. (1999). "Bacteriology and Clinical Course of Camel-Bite Wound Infections". European Journal of Clinical Microbiology & Infectious Diseases. 18 (12): 918–919. doi:10.1007/s100960050433. ISSN 0934-9723.
  6. 6.0 6.1 "CDC Vaccines and Immunizations - Tetanus".
  7. 7.0 7.1 "Advisory Committee on Immunization Practices (ACIP) for postexposure prophylaxis (PEP) to prevent human rabies (CDC. Human rabies prevention)".
  8. Dog Bite Prevention. CDC. http://www.cdc.gov/features/dog-bite-prevention/ Accessed on February 10, 2016

Template:Injuries, other than fractures, dislocations, sprains and strains